Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

CVS Health survey shows mental health concerns continue to rise


Concerns higher than during COVID-19 pandemic, with the effects of social media a driving factor

WOONSOCKET, R.I., May 9, 2024 /PRNewswire/ -- A recent CVS Health® (NYSE: CVS)/Morning Consult survey found that a majority of adults have significant concerns about their mental health and rates across the country continue to rise.

"Mental health became a top concern in 2020 and it has only risen since," said Taft Parsons III, M.D., Vice President and Chief Psychiatric Officer, CVS Health. "Uncertainty around the future, current events and social media continue to drive anxiety among adults. Our priority, across CVS Health, remains improving access to quality virtual and in-person mental health care and ensuring we have resources in place to address the unique needs of individuals."

Americans are concerned about social media's implications on their mental health

The survey also found that nearly four in 10 adults (37%) believe social media has hurt society at-large.

"Our increasing use of technology has helped increase access to mental health care ? CVS Health has had over 43 million mental health virtual visits since 2020 ? and created a way for people to talk openly about the topic, reducing stigma," added Parsons III. "But as we navigate the impacts social media has on mental health, it has become increasingly important that we highlight its limitations and set guardrails for ourselves and our children."

CVS Health's commitment to mental health care

As the leading health solutions company with resources that expand nationally and in communities across the country, CVS Health continues to increase accessibility to both in-person and virtual mental health services:

For more information on how CVS Health is making mental well-being services more accessible, less complicated and more convenient, visit CVSHealth.com.

Methodology  

This poll was conducted by Morning Consult between March 19-21, 2024, among a national sample of 2,202 adults. The margin of error for the full sample is plus or minus two percentage points. The interviews were conducted online and the data were weighted to approximate a target sample of adults based on age, gender, educational attainment, race, and region.

  1. Measured via PHQ-9 scores for patients who have completed more than one visit and reported having at least mild depression symptoms in their initial visit. Percentages do not add up to 100% due to rounding.

About CVS Health
CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues ? including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health ? whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system ? and their personal health care ? by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

Media Contacts
Ethan Slavin
[email protected] 

Doug Feingold
[email protected]

 

SOURCE CVS Health


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: